The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF CHRONIC KIDNEY DISEASE

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 20 January 2025, the application for the phase II clinical trial of class 1 innovative new drug UBT251 Injection self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, on indication of chronic kidney disease ("CKD") was approved by China National Medical Products Administration, with reference number of CXHL2401227.

UBT251 is a long-acting triple agonist of GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulinotropic polypeptide) /GCG (glucagon), demonstrating potent activity on these receptors. Metabolic syndrome caused by obesity, diabetes and other factors damages the kidneys through mechanisms such as altering hemodynamics, increasing intraglomerular pressure, oxidative stress and inflammation, leading to a significant rise in the prevalence of CKD in recent years. While GLP-1 agonist semaglutide has demonstrated efficacy in phase III clinical trials for CKD treatment, UBT251 has shown superior therapeutic effects compared to semaglutide in relevant preclinical animal studies of CKD.

Furthermore, UBT251 obtained clinical trial approval in China in 2023 on indications of adult type 2 diabetes, overweight or obesity and non-alcoholic fatty liver disease ("NAFLD"), with clinical trials currently progressing smoothly and demonstrating confirmed efficacy and safety.

As the first domestically chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in China, UBT251 positions the Company as a key player in the R&D of this type of drug. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 22 January 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.